Ind Swift Laboratories Ltd vs Marksans Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 137.15 as of 30 Apr 15:30 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 8.7 on March 2021 to 26.5 on March 2025 . This represents a CAGR of 24.95% over 5 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 2044 crore on March 2021 to ₹ 10076 crore on March 2025 . This represents a CAGR of 37.58% over 5 years The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The revenue of Marksans Pharma Ltd for the Dec '25 is ₹ 774.57 crore as compare to the Sep '25 revenue of ₹ 741.98 crore. This represent the growth of 4.39% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The ebitda of Marksans Pharma Ltd for the Dec '25 is ₹ 180.89 crore as compare to the Sep '25 ebitda of ₹ 166.07 crore. This represent the growth of 8.92% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The net profit of Marksans Pharma Ltd changed from ₹ 89.07 crore to ₹ 113.69 crore over 7 quarters. This represents a CAGR of 14.97% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.4 % on March 2021 to 19.26 % on March 2025 . This represents a CAGR of 13.12% over 5 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Marksans Pharma Ltd

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982.
Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005.
The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
Marksans Pharma Limited (formerly M/s.

FAQs for the comparison of Ind-Swift Laboratories Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Marksans Pharma Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,190 Cr while Market cap of Marksans Pharma Ltd is 8,367 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Marksans Pharma Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Marksans Pharma Ltd?

As of May 3, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹137.15. On the other hand, Marksans Pharma Ltd stock price is INR ₹184.65.

How do dividend payouts of Ind-Swift Laboratories Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.